Relapsed Cancer
28
11
14
5
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
17.9%
5 terminated out of 28 trials
50.0%
-36.5% vs benchmark
4%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (28)
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Individualized Treatments in Adults With Relapsed/Refractory Cancers
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
Plan Development for Giving Teclistamab in the Outpatient Setting
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
A Study to Investigate LYL797 in Adults With Solid Tumors
A Biomarker Screening Protocol for Participants With Solid Tumors
Three Times Weekly Symptom Screening for Children With Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA)
Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory AML or MDS
Impact of Human-Animal Interactions on Children With Life-Threatening Conditions and Their Parents